Company news
Tvardi Therapeutics, Inc. (NASDAQ:TVRD) news
Every Tvardi Therapeutics, Inc. press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases — page 2
Cara Therapeutics Announces Fourth Quarter and Full Year 2022 Financial Results
March 6, 2023
Cara Therapeutics to Announce Fourth Quarter and Full Year 2022 Financial Results on March 6, 2023
February 21, 2023
Cara Therapeutics Announces Results from the KOMFORT Phase 2 Trial of Oral Difelikefalin for the Treatment of Pruritus in Notalgia Paresthetica Published in the New England Journal of Medicine
February 8, 2023
Cara Therapeutics to Host Capital Markets Day on Thursday, February 16, 2023
January 17, 2023
Cara Therapeutics Announces Presentation at the 41st Annual J.P. Morgan Healthcare Conference
January 3, 2023
Cara Therapeutics Reports Third Quarter 2022 Financial Results
November 7, 2022
Cara Therapeutics Announces Appointment of Lisa von Moltke, M.D., to its Board of Directors
November 3, 2022
Cara Therapeutics to Present at Upcoming Investor Conferences
November 2, 2022
Cara Therapeutics to Announce Third Quarter 2022 Financial Results on November 7, 2022
October 24, 2022
SWK Holdings' Subsidiary, Enteris BioPharma, Receives $5 Million Milestone Payment from Cara Therapeutics
October 10, 2022
Cara Therapeutics Announces Difelikefalin (KORSUVA®) Injection New Drug Application Has Been Submitted in Japan
September 28, 2022
Cara Therapeutics Appoints Ryan Maynard as Chief Financial Officer
September 12, 2022
Cara Therapeutics Presents Late-Breaking Results of the KOMFORT Phase 2 Trial of Oral Difelikefalin for Pruritus in Notalgia Paresthetica at the 31st EADV Congress
September 8, 2022
Cara Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment Conference
September 6, 2022
Cara Therapeutics to Host Virtual Notalgia Paresthetica Event on September 20, 2022
August 24, 2022
Cara Therapeutics Announces KOMFORT Data Accepted for Late-Breaking Presentation at the 31st EADV Congress
August 22, 2022
Kapruvia® approved in Switzerland with additional regulatory decisions expected in H2 2022
August 19, 2022
Cara Therapeutics Reports Second Quarter 2022 Financial Results
August 8, 2022
Cara Therapeutics to Present at the Canaccord Genuity 42nd Annual Growth Conference
August 3, 2022
Cara Therapeutics to Announce Second Quarter 2022 Financial Results on August 8, 2022
August 1, 2022
Cara Therapeutics Announces Positive Topline Results from KOMFORT Phase 2 Trial of Oral Difelikefalin for the Treatment of Pruritus in Patients with Notalgia Paresthetica
June 30, 2022
Cara Therapeutics Reports First Quarter 2022 Financial Results
May 9, 2022
Cara Therapeutics to Present at May Investor Conferences
May 3, 2022
Cara Therapeutics to Announce First Quarter 2022 Financial Results on May 9, 2022
April 29, 2022
Kapruvia® approved by European Commission for the treatment of moderate-to-severe pruritus in hemodialysis patients
April 28, 2022
Cara Therapeutics to Present at the 21st Annual Needham Virtual Healthcare Conference
April 5, 2022
Cara Therapeutics Announces Biomarker Data from KALM-1 and KALM-2 Trials of KORSUVA™ (difelikefalin) Injection Selected for Presentation at National Kidney Foundation Spring Clinical Meetings 2022
April 4, 2022
Cara Therapeutics Announces Oral KORSUVA™ (difelikefalin) Improves Itch and Inflammatory Biomarkers in Atopic Dermatitis Patients with Moderate-To-Severe Pruritus
March 28, 2022
Cara Therapeutics Announces Oral KORSUVA™ (difelikefalin) Data Selected for Late-Breaking Presentation at 2022 American Academy of Dermatology Annual Meeting
March 8, 2022
Cara Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results
March 1, 2022
Kapruvia® receives positive CHMP opinion for the treatment of moderate-to-severe pruritus in hemodialysis patients
February 28, 2022
Cara Therapeutics to Announce Fourth Quarter and Full Year 2021 Financial Results on March 1, 2022
February 22, 2022
Cara Therapeutics to Host Virtual R&D Day on March 11, 2022
February 18, 2022
Cara Therapeutics Announces Difelikefalin (KORSUVA™) Injection Achieves Positive Topline Results in Phase 3 Clinical Study in Japan for the Treatment of Pruritus in Hemodialysis Patients
January 10, 2022
Cara Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference
January 3, 2022
Cara Therapeutics Announces CMS Grants TDAPA to KORSUVA™ (difelikefalin) Injection
December 20, 2021
Cara Therapeutics to Present at the Piper Sandler 33rd Annual Virtual Healthcare Conference
November 18, 2021
Cara Therapeutics Reports Third Quarter 2021 Financial Results
November 8, 2021
Cara Therapeutics Announces CEO Transition
November 3, 2021
Cara Therapeutics to Announce Third Quarter 2021 Financial Results on November 8, 2021
November 1, 2021
Cara Therapeutics Presents Late-Breaking Results of KARE Phase 2 Trial of Oral Difelikefalin (Oral KORSUVA™) in Atopic Dermatitis Patients with Moderate-to-Severe Pruritus at the 2021 European Academy of Dermatology and Venereology (EADV) Virtual Congress
October 4, 2021
Cara Therapeutics Announces Late-Breaking Presentation at 2021 European Academy of Dermatology and Venereology (EADV) Virtual Congress
September 29, 2021
Cara Therapeutics to Present at the the 2021 Cantor Virtual Global Healthcare Conference
September 24, 2021
Vifor Pharma and Cara Therapeutics announce U.S. FDA approval of KORSUVA™ injection for the treatment of moderate-to-severe pruritus in hemodialysis patients
August 24, 2021
Cara Therapeutics and Vifor Pharma announce U.S. FDA approval of KORSUVA™ (difelikefalin) injection for the treatment of moderate-to-severe pruritus in hemodialysis patients
August 23, 2021
Cara Therapeutics Reports Second Quarter 2021 Financial Results
August 9, 2021
Cara Therapeutics to Announce Second Quarter 2021 Financial Results on August 9, 2021
August 2, 2021
SWK Holdings' Subsidiary, Enteris BioPharma, Receives $10 Million Milestone Payment from Cara Therapeutics
June 11, 2021
Cara Therapeutics Reports First Quarter 2021 Financial Results
May 10, 2021